Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

AbbVie Announces Offer Consideration For Acquisition Of Pharmacyclics

NORTH CHICAGO, Ill., May 21, 2015 /PRNewswire/ — AbbVie (NYSE: ABBV) announced today the per share offer consideration amounts pursuant to its previously announced offer to acquire each outstanding share of common stock of Pharmacyclics, Inc. (“Pharmacyclics”) for a mix of cash and AbbVie common stock, as described in the Registration Statement on Form S-4 filed […]

Read More »

Achillion partners with J&J to develop hepatitis C drugs

Achillion Pharmaceuticals Inc said it will collaborate with Johnson & Johnson to develop and market its hepatitis C drugs including an oral regimen that could work on all genotypes and shorten treatment time. Achillion will be eligible for milestone payments of up to $1.1 billion related to the development, regulatory approval and sales of the […]

Read More »

GW Pharma Relocates CEO and Taps Ex-Allergan Exec to Lead U.S. Biz in SoCal

GW Appoints Senior Industry Executive to President, North America and Relocates CEO to the U.S. U.S. Operations to be Located in Southern California LONDON, May 19, 2015 (GLOBE NEWSWIRE via COMTEX) — GW Pharmaceuticals plc (“GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary […]

Read More »

Boehringer Ingelheim acquires Pharmaxis’ phase 1 anti-inflammatory drug candidate

FRENCHS FOREST, Australia & INGELHEIM, Germany–(BUSINESS WIRE)–Boehringer Ingelheim and pharmaceutical company Pharmaxis (ASX: PXS) announce that Boehringer Ingelheim has exercised its option and acquired the investigational drug PXS4728A, to develop it for the treatment of the liver-related condition NASH and to prevent its consequences. PXS4728A is a Semicarbazide-Sensitive Amine Oxidase/Vascular Adhesion Protein-1 (SSAO/VAP-1) Inhibitor discovered […]

Read More »

Endo to Acquire Par Pharmaceutical, Strategically Expanding Generics Business to a Top 5 Industry Leader

DUBLIN and WOODCLIFF LAKE, N.J., May 18, 2015 /PRNewswire/ — • Transaction valued at $8.05 billion is transformative for Endo, creating a powerful platform for future growth and further strategic M&A• Creates specialty pharmaceutical company with one of industry’s fastest growing generics businesses and expanded product portfolio, pipeline, technology platform and manufacturing capabilities• Positions Endo […]

Read More »

Johnson & Johnson Commits $25 Million to Operation Smile Over Next Five Years

NEW YORK, May 18, 2015 /PRNewswire/ — Hundreds gathered Thursday night at Cipriani 42nd Street in New York to recognize those who have supported Operation Smile, the world’s largest medical charity of its kind providing free cleft surgery and care. Johnson & Johnson committed $25 million in financial and product contributions to Operation Smile over the […]

Read More »

BioPharma M&A: Capital Efficiency Drives Returns

Amidst lofty public markets and robust fund flows, it’s easy to forget the importance of equity capital efficiency in building new biotech companies. But like gravity, it’s a fundamental principle and rests at the heart of generating quality returns in any market. By deploying early, expensive equity dollars carefully and thoughtfully, a startup can preserve […]

Read More »

Is Sir Andrew Witty The Person To Lead A Major Pharmaceutical Company?

The success of a CEO is often predicated on the situational status of the company he or she inherits. Bill Steere took the helm at Pfizer in 1991, riding on the crest of five recently launched blockbusters: Zoloft, Norvasc, Zithromax, Diflucan, and Cardura. He then oversaw the rollout of Viagra and, if all this wasn’t […]

Read More »

U.S. class action asserts India’s Ranbaxy manipulated FDA rules

A Ranbaxy office building is pictured in the northern Indian city of Mohali May 14, 2013. Reuters/Ajay Verma Indian generic drugmaker Ranbaxy Laboratories Ltd has been sued in a district court in the United States for allegedly manipulating U.S. Food and Drug Administration rules for years to keep rival generic drugs out of the market. […]

Read More »

Ogilvy CommonHealth Worldwide’s Jill Lesiak Honored as HBA Rising Star

PARSIPPANY, NJ–(Marketwired – May 14, 2015) – Ogilvy CommonHealth Worldwide (, the health behavior change experts of Ogilvy & Mather (, and a WPP company (NASDAQ: WPPGY) (, today announced Jill Lesiak, vice president, creative director at the network’s Parsippany-based agency, Ogilvy CommonHealth, was named an industry Rising Star by the Healthcare Businesswomen’s Association (HBA) […]

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

April 2019 Focus: Healthcare agency & network profiles, industry overview & awards, and more!


Ad Right Bottom